SCHEMBL4746038

SCHEMBL4746038

CNc1nc2ccc(C(=O)O)cc2s1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LDHA P00338 1/20 0.61
SMN1; SMN2 Q16637 6/20 0.59
KDM4E B2RXH2 3/20 0.57
NFKB1 P19838 2/20 0.57
NFKB2 Q00653 2/20 0.57
RELA Q04206 2/20 0.57
LMNA P02545 2/20 0.57
HSD17B10 Q99714 5/20 0.57
DYRK1A Q13627 1/20 0.56
PIK3CA P42336 1/20 0.55
PIK3CB P42338 1/20 0.55
PIK3CG P48736 1/20 0.55
PI4KB Q9UBF8 1/20 0.55
NPC1 O15118 4/20 0.54
RAB9A P51151 4/20 0.54
GAA P10253 2/20 0.54
MAPT P10636 2/20 0.54
HPGD P15428 2/20 0.54
KLF5 Q13887 2/20 0.54
MITF O75030 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7559825 0.88 SMN1; SMN2 (0.67) LDHASMN1; SMN2HSD17B10DYRK1ANPC1
SCHEMBL6058154 0.85 DYRK1A (0.77) SMN1; SMN2LMNAHSD17B10DYRK1APIK3CA
SCHEMBL19202176 0.85 PIK3CA (0.75) LDHASMN1; SMN2KDM4ELMNAHSD17B10
SCHEMBL13853337 0.84 HSD17B10 (0.61) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL4970256 0.84 KDM4E (0.58) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL23628970 0.84 SMN1; SMN2 (0.54) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL19921646 0.84 HSD17B10 (0.60) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL31087734 0.84 SMN1; SMN2 (0.54) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL14509001 0.82 NPC1 (0.66) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL24729341 0.82 HSD17B10 (0.73) SMN1; SMN2KDM4EHSD17B10NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024179405-A1 CLASS OF CINNAMAMIDE DERIVATIVES AND APPLICATION THEREOF 上海交通大学 2024-09-06 WO disclosed
CN-118546081-A Cinnamide derivative and application thereof 上海交通大学 2024-08-27 CN disclosed
US-20240254110-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 CANCER RESEARCH TECH LTD (GB) 2024-08-01 US disclosed
US-11787786-B2 Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-10-17 US disclosed
US-20220220097-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2022-07-14 US disclosed
EP-3521286-B1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 CANCER RESEARCH TECH LTD (GB) 2021-09-29 EP disclosed
US-11124501-B2 Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-09-21 US disclosed
EP-3521286-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 Cancer Research Technology Ltd. (GB) 2019-08-07 EP disclosed
US-20190106413-A1 INHIBITOR COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-04-11 US disclosed
EP-3052492-B1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 CANCER RESEARCH TECH LTD (GB) 2019-03-27 EP disclosed
US-10189821-B2 Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-01-29 US disclosed
US-9701664-B2 Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2017-07-11 US disclosed
US-20170037036-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR I CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2017-02-09 US disclosed
US-20160289216-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-10-06 US disclosed
EP-3052492-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 Cancer Research Technology Limited (GB) 2016-08-10 EP disclosed
WO-2015049535-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2015-04-09 WO disclosed
WO-2008124393-A1 BENZOTHIAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190106413-A1 INHIBITOR COMPOUNDS HSF1, HSP90AB1, HSP90AA1 LDHA 2816/4885SMN1; SMN2 3616/4885KDM4E 3104/4885
US-10189821-B2 Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I HSF1, HSP90AB1, HSPB1 LDHA 2608/4885SMN1; SMN2 3744/4885KDM4E 2988/4885
US-20240254110-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 HSF1, HSP90AB1, HSPB1 LDHA 2608/4885SMN1; SMN2 3618/4885KDM4E 2892/4885
US-20170037036-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR I HSF1, HSP90AB1, HSPB1 LDHA 2608/4885SMN1; SMN2 3744/4885KDM4E 2988/4885
US-20160289216-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 HSF1, HSP90AB1, HSPB1 LDHA 2646/4885SMN1; SMN2 3787/4885KDM4E 2977/4885
US-11787786-B2 Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 HSF1, HSP90AB1, HSPB1 LDHA 2608/4885SMN1; SMN2 3618/4885KDM4E 2892/4885
US-20220220097-A1 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 HSF1, HSP90AB1, HSPB1 LDHA 2608/4885SMN1; SMN2 3618/4885KDM4E 2892/4885
US-11124501-B2 Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I HSF1, HSP90AB1, HSPB1 LDHA 2608/4885SMN1; SMN2 3744/4885KDM4E 2988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.